CN102512663A - Application of nerve growth factor in preparing medicines for treating pruritus - Google Patents
Application of nerve growth factor in preparing medicines for treating pruritus Download PDFInfo
- Publication number
- CN102512663A CN102512663A CN2011104159282A CN201110415928A CN102512663A CN 102512663 A CN102512663 A CN 102512663A CN 2011104159282 A CN2011104159282 A CN 2011104159282A CN 201110415928 A CN201110415928 A CN 201110415928A CN 102512663 A CN102512663 A CN 102512663A
- Authority
- CN
- China
- Prior art keywords
- growth factor
- application
- nerve growth
- injection
- pruritus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention discloses an application of a nerve growth factor (NGF) in preparing medicines and daily chemical products for treating pruritus. According to the invention, an effective therapeutic method for pruritus can be provided, and a novel approach for improving the life quality of pruritus patients is provided.
Description
Technical field
The invention belongs to medical technical field, be specifically related to the application of nerve growth factor in preparation treatment skin pruritus disease medicament.
Background technology
(Nerve Growth Factor is a kind of micromolecule polypeptide class neurotrophic factor NGF) to nerve growth factor, has stronger short cell division function, plays an important role aspect many at neurodevelopment, neuranagenesis etc.
In recent years; NGF is with its unique mechanism of action and advantage; Be widely used clinically; Mainly concentrate on the following aspects: (1) nervus centralis disease (Central Nerve System, CNS): cerebral apoplexy, spinal cord injury, craniocerebral trauma, neonatal hypoxic ischemic encephalopathy and Alzheimer (Alzheimer ' s Disease, AD) etc.; (2) peripheral nerve injury and peripheral nerve disease (Peripheral Nerve System, PNS): diabetic peripheral neuropathy, the injury repairing of nervus facialis, organophosphate poisoning tardy property peripheral neuritis and injury of sciatic nerve etc.; (3) ocular disease: treatment neurotrophic corneal ulcer, optic neuritis, promotion cornea wound healing etc.
Skin pruritus is one of clinical patient common skin disease, especially is more common in the old people.It is main it is characterized by with pruritus, and does not have primary lesion.According to the difference of pruritus scope, clinically it is divided into two kinds of limitation and generals.
Skin pruritus is no former breakout, will have only skin pruritus clinically and not have the primary cutaneous impairer to be referred to as pruritus.The category that belongs to the traditional Chinese medical science " pruritus ".Skin pruritus is divided plain edition and anaphylactic type.But whole body takes place, and is many with face, the back of the body and extremity especially.The plain edition skin pruritus generally is that the skin too dry causes, and the cause of disease of skin pruritus is still not clear, thinks relevant with some disease, like diabetes, hepatopathy, nephropathy etc. more; Simultaneously also with some extraneous factors stimulate relevant, like cold, warm, chemical & blended fabric etc.
In above-mentioned disease, the patient scratches owing to being difficult to stand pruritus, tends to cause secondary affection, causes infringements such as the hyperemia of pruritus position, ulceration, lichen appearance words, pigmentation, also can have a sleepless night because of itching and maybe can not sleep peacefully.This not only perplexs extensive patients, also is the thorny difficult problem that the dermatologist feels.At present, the Western medicine of treatment skin pruritus commonly used has antihistaminic (quick enlightening, clarityne) calcium preparation (common calcium tablet, necessity gives injection) and hormone (containing the dexamethasone class) etc.Because these medicine contraindications are many, often cause drowsiness, weak and other side effect, influence patient's orthobiosis and work.
Skin pruritus belongs to neural spirituality dermatosis, is a kind of skin neurosis illness, perhaps can solve the problem of skin pruritus so infer micromolecule polypeptide class neurotrophic factor NGF, and existing do not have research to show that NGF has the function of treatment skin pruritus as yet.
Summary of the invention
The object of the present invention is to provide the application of nerve growth factor in preparation treatment skin pruritus disease medicament.
Preferably, nerve growth factor described in the above-mentioned application adopts topical administration.
Preferably, nerve growth factor described in the above-mentioned application adopts drug administration by injection.
Preferably, nerve growth factor described in the above-mentioned application adopts the subcutaneous injection administration.
Preferably, nerve growth factor described in the above-mentioned application adopts administered intramuscular.Preferably, nerve growth factor described in the above-mentioned application adopts percutaneous or mucosal route administration.
Preferably, nerve growth factor described in the above-mentioned application adopts nasal mucosa medicine administration.
Preferably, the dosage form of said nasal mucosa medicine administration is that nasal spray, nasal drop, nose are with solution, nasal obstruction agent and nose aerosol.
Preferably, said skin pruritus disease is the skin pruritus that mosquito bite causes.
Preferably, said skin pruritus disease is old people's skin pruritus.Preferably, the patient of skin pruritus disease described in the above-mentioned application is the old people.
Preferably, said skin pruritus is the geroderma pruritus that unknown cause causes.Preferably, said skin pruritus is the geroderma pruritus that is caused by basic disease.Preferably, said basic disease is hypertension, hepatic disease, kidney disease, cancer, diabetes.
Preferably, the dosage of said nerve growth factor was 5～400 microgram/days, preferably 10～100 microgram/days.Preferably the dosage of said nerve growth factor was 30～50 microgram/days, was preferably for 30 microgram/days.
(Nerve Growth Factor is a kind of micromolecule polypeptide class neurotrophic factor NGF) to nerve growth factor, has stronger short cell division function, plays an important role aspect many at neurodevelopment, neuranagenesis etc.But in clinical practice, the inventor is surprised to find that nerve growth factor has the significant effect of improving for skin pruritus.
Pruritus is a kind of subjective symptoms, and pathogeny is still imprecise, it is generally acknowledged that the free nerve endings that reaches high dermis in the epidermis is the sensor that pruritus is felt; Sensor receives to cause chemical mediators such as local histamine, kassinin kinin and protease to discharge after physics, the chemical stimulation; These chemical mediators act on teleneuron and cause impulsion, no sheath cell tissue fibers conduction in the pain nerve fiber, via spinothalamic tract to thalamus; Arrive the cerebral cortex sensory region at last, produce tickle and itch.
Through enforcement of the present invention, a kind of effective Therapeutic Method to skin pruritus can be provided, for the quality of life of improving the pruritus crowd provides a kind of new approach.
The specific embodiment
Below in conjunction with Test Example the present invention is done further explanation, following embodiment only limits to explain the present invention, and should not be regarded as limiting protection scope of the present invention.
The skin pruritus that clinical trial example 1 treatment mosquito bite causes
1.1 physical data: this group patient 125 examples, wherein male 60 examples, women 65 examples, 18～51 years old age.
1.2 method for using:
1.2.1 medicine: injection mouse nerve growth factor (Soviet Union's peptide is given birth to Shutaishen (Beijing) Pharmaceutical Co., Ltd.), essential balm is as matched group
1.2.2 concrete method for using: directly medicine is smeared every day 2～3 times, SM 1～5 day during mosquito bite aftersensation pruritus
Method for preparation of drug: get one bottle of injection mouse nerve growth factor (30 μ g/ bottle), inject 2mL physiological saline solution mix homogeneously, get the NGF solution of 15 μ g/mL, preserve subsequent use in 2～8 ℃ of refrigerators.
1.2.3 criterion of therapeutical effect: see table 1
Table 1 criterion of therapeutical effect
| Classification | Standard |
| Cure | Erythra and scratchiness disappear fully |
| Produce effects | Erythra disappears basically, and scratchiness is conscious to be alleviated |
| Effectively | Deflorescence is more than 50% |
| Invalid | Treat after 5 days erythra and scratchiness and do not see improvement |
1.3 therapeutic outcome
Table 2 therapeutic outcome
| Medicine | Number of users | Cure | Produce effects | Effectively | Invalid | Total effective rate |
| Essential balm | 62 | 11(18％) | 26(42％) | 25(40％) | 60％ | |
| NGF | 63 | 51(81％) | 9(14％) | 2(3％) | 1(2％) | 98％ |
Can be known that by last table 2 essential balm can not be cured the pruritus that mosquito bite causes basically, total effective rate can reach 60%; And injection mouse nerve growth factor of the present invention is when being used for pruritus that mosquito bite causes, and cure rate can reach 81%, and total effective rate has reached 98%.
Clinical trial example 2 treatment old people skin pruritus
1.1 physical data: this organizes 280 routine patients, male 160 examples, women 120 examples, age 55-86 year, average 72.5 years old.The course of disease is the shortest 1 year, and is the longest 5 years, average 2.6 years.Wherein, among the said patient 280 routine patients, with basic disease like the patient of hypertension, liver, kidney, cancer, diabetes totally 165 examples, be divided into three groups (essential balm group, NGF percutaneous dosing group, NGF nasal-cavity administration group, NGF injection groups) at random.
Except that patient main suit's pruritus misery, extremity and trunk visible obviously scratch, blood crusts are simultaneously with vexed, insomnia.
1.2 Therapeutic Method:
1.2.1 medicine: injection mouse nerve growth factor (Soviet Union's peptide is given birth to Shutaishen (Beijing) Pharmaceutical Co., Ltd.), mouse nerve growth factor nasal spray (the clear new drug development center of spreading out, Beijing provides) uses essential balm as contrast.
1.2.2 concrete method for using
The intramuscular injection group: every bottle of injection mouse nerve growth factor (30 μ g/ bottle) dissolves with 0.5ml sodium chloride injection (or sterilized water for injection) before facing usefulness, in 2～8 ℃ of refrigerators, stores to get final product.μ g every days 30 (one bottle), 1 time on the one, 3～6 weeks were a course of treatment;
The percutaneous dosing group: every bottle of injection mouse nerve growth factor (30 μ g/ bottle) dissolves with 0.5ml sodium chloride injection (or sterilized water for injection) before facing usefulness, in 2～8 ℃ of refrigerators, stores to get final product.Medicine directly is applied on the skin every day 2～3 times, 3～6 weeks of SM;
The nasal-cavity administration group: every bottle of injection mouse nerve growth factor (30 μ g/ bottle) dissolves with 0.5ml sodium chloride injection (or sterilized water for injection) before facing usefulness; With gained NGF filled with solution (1mL/ bottle) in jetmizer, place to store in 2～8 ℃ of refrigerators to get final product then.One bottle of every day, 2 times on the one every side 0.125ml of bilateral nostril administration, 3～6 weeks were a course of treatment.
1.3 criterion of therapeutical effect: see table 3
Table 3 criterion of therapeutical effect
1.4 therapeutic effect: see table 4
Table 4 therapeutic outcome
Can be known that by last table 4 essential balm can not be cured old people's skin pruritus basically, total effective rate only has 42%; And injection mouse nerve growth factor of the present invention no matter administering mode be directly smear, nasal-cavity administration or injection; Cure rate all can reach more than 70%; Total effective rate has all reached 97%, wherein uses the direct injection approach, and cure rate and total effective rate are higher; Can reach 84%, total effective rate has reached 100%.
Simultaneously, in drug use process of the present invention, do not find that side effect such as drowsiness, Liver and kidney toxicity appear in any patient.
The above is merely preferred embodiment of the present invention, and is in order to restriction the present invention, not all within spirit of the present invention and principle, any modification of being done, is equal to replacement, improvement etc., all should be included within protection scope of the present invention.
Claims (10)
1. the application of nerve growth factor in the medicine of preparation treatment skin pruritus disease.
2. according to the said application of claim 1, it is characterized in that said nerve growth factor adopts drug administration by injection.
3. according to the said application of claim 2, it is characterized in that said nerve growth factor adopts the subcutaneous injection administration.
4. according to the said application of claim 2, it is characterized in that said nerve growth factor adopts administered intramuscular.
5. according to the said application of claim 2, the dosage form that it is characterized in that said drug administration by injection is solution type injection agent, floating type injection, emulsion-type injection, injection freeze-dried powder or injectable sterile powder.
6. according to the said application of claim 1, it is characterized in that said nerve growth factor adopts percutaneous or mucosal route administration.
7. according to the said application of claim 6, it is characterized in that said nerve growth factor adopts nasal mucosa medicine administration.
8. according to the said application of claim 7, the dosage form that it is characterized in that said nasal mucosa medicine administration is that nasal spray, nasal drop, nose are with solution, nasal obstruction agent and nose aerosol.
9. according to the arbitrary said application of claim 1～8, it is characterized in that said skin pruritus disease is old people's skin pruritus.
10. according to the arbitrary said application of claim 1～8, the dosage that it is characterized in that said nerve growth factor was 5～400 microgram/days, was preferably for 10～100 microgram/days.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201110415928 CN102512663B (en) | 2010-12-31 | 2011-12-14 | Application of nerve growth factor in preparing medicines for treating pruritus |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201010615769.6 | 2010-12-31 | ||
| CN201010615769 | 2010-12-31 | ||
| CN 201110415928 CN102512663B (en) | 2010-12-31 | 2011-12-14 | Application of nerve growth factor in preparing medicines for treating pruritus |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102512663A true CN102512663A (en) | 2012-06-27 |
| CN102512663B CN102512663B (en) | 2013-10-23 |
Family
ID=46283914
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 201110415928 Active CN102512663B (en) | 2010-12-31 | 2011-12-14 | Application of nerve growth factor in preparing medicines for treating pruritus |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102512663B (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101035551A (en) * | 2004-10-19 | 2007-09-12 | 碧雅诗株式会社 | Nerve growth factor production inhibitor and external preparation for skin, cosmetic, quasi medicine, itch prophylactic and therapeutic agent and atopic dermatitis therapeutic agent mixed with the ner |
-
2011
- 2011-12-14 CN CN 201110415928 patent/CN102512663B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101035551A (en) * | 2004-10-19 | 2007-09-12 | 碧雅诗株式会社 | Nerve growth factor production inhibitor and external preparation for skin, cosmetic, quasi medicine, itch prophylactic and therapeutic agent and atopic dermatitis therapeutic agent mixed with the ner |
Non-Patent Citations (1)
| Title |
|---|
| 李萍 等: "神经生长因子在特应性皮炎患者血中的检测及意义", 《十五次全国皮肤性病学术年会》, 16 June 2009 (2009-06-16), pages 93 - 94 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102512663B (en) | 2013-10-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101800851B1 (en) | Local anesthesia pain-relieving time-delay angent | |
| CN102198091B (en) | Acupuncture point injection | |
| Peng et al. | Effect of hyperbaric oxygen therapy on patients with herpes zoster | |
| JP3989188B2 (en) | Bee venom therapy without a bee needle | |
| CN102512663B (en) | Application of nerve growth factor in preparing medicines for treating pruritus | |
| CN107349310B (en) | Traditional Chinese medicine composition for treating cancer pain and application thereof | |
| CN103272195B (en) | Traditional Chinese medicine paste for treating pain | |
| JP4383678B2 (en) | Oil-in-water emulsions for use as pharmaceuticals | |
| CN107496525A (en) | A kind of Chinese medicine composition for treating cancer pain disease and its application | |
| CN105168503B (en) | It is a kind of to be used to prevent external medicine composition of radiodermatitis and preparation method thereof | |
| CN101829328A (en) | Drug for treating amphetamine-type exhilarant dependence syndrome and amphetamine-type exhilarant and opioid mixed dependence syndrome | |
| CN104800264B (en) | One kind carries medicine acupuncture needle and application thereof | |
| CN102205023A (en) | Powder for diminishing inflammation and healing trauma | |
| CN117018158B (en) | Graphene acupoint plaster for warming uterus and relieving pain as well as preparation method and application thereof | |
| CN101411700B (en) | Use of 5,7,4'-trihydroxy flavanone or derivative thereof for analgesia | |
| CN108635418A (en) | A kind of little Jin gel combinations and preparation method thereof and purposes | |
| RU2814362C1 (en) | Method of treating rosacea with solid persistent oedema by points | |
| CN102370777A (en) | Medicament for treating non-ulcerated chilblains | |
| CN109954127A (en) | A kind of placental peptide injection | |
| CN105998335A (en) | Tranquilizing traditional Chinese medicine composition gel and preparation method thereof | |
| CN1234369C (en) | Bacillus prodigiosus polysaccharide for nose drops | |
| CN108939041A (en) | A kind of placental peptide injection | |
| CN1086295C (en) | Exterior-applied medical liquor | |
| CN100998604A (en) | Traditional Chinese medicine for treat burns and scald and its preparing method | |
| CN102920684B (en) | Tetradotoxin mask and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |